Sodium–Glucose Cotransporter Protein 2 Inhibitors: Novel Application for the Treatment of Obesity-Associated Hypertension
Yilan Hu,Jiaqi Bao,Zhicheng Gao,Lifang Ye,Lihong Wang
DOI: https://doi.org/10.2147/dmso.s446904
2024-01-26
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Yilan Hu, 1, 2 Jiaqi Bao, 1, 2 Zhicheng Gao, 1, 2 Lifang Ye, 2 Lihong Wang 1, 2 1 The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China; 2 Heart Center, Department of Cardiovascular Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, People's Republic of China Correspondence: Lihong Wang, Heart Center, Department of Cardiovascular Medicine, Zhejiang, Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, People's Republic of China, Email Obesity is becoming increasingly prevalent in China and worldwide and is closely related to the development of hypertension. The pathophysiology of obesity-associated hypertension is complex, including an overactive sympathetic nervous system (SNS), activation of the renin–angiotensin–aldosterone system (RAAS), insulin resistance, hyperleptinemia, renal dysfunction, inflammatory responses, and endothelial function, which complicates treatment. Sodium–glucose cotransporter protein 2 (SGLT-2) inhibitors, novel hypoglycemic agents, have been shown to reduce body weight and blood pressure and may serve as potential novel agents for the treatment of obesity-associated hypertension. This review discusses the beneficial mechanisms of SGLT-2 inhibitors for the treatment of obesity-associated hypertension. SGLT-2 inhibitors can inhibit SNS activity, reduce RAAS activation, ameliorate insulin resistance, reduce leptin secretion, improve renal function, and inhibit inflammatory responses. SGLT-2 inhibitors can, therefore, simultaneously target multiple mechanisms of obesity-associated hypertension and may serve as an effective treatment for obesity-associated hypertension. Keywords: sodium-glucose cotransporter protein 2 inhibitors, obesity-associated hypertension, metabolism, neuro-humoral regulation, inflammation Since the 1990s, China's economy has grown rapidly and people's lifestyles have changed considerably, 1 with a concurrent rapid increase in the prevalence of obesity. China now has the largest number of people with obesity worldwide. 2,3 Obesity is a major risk factor for non-communicable diseases, presenting a great public health and economic burden. 3,4 Hypertension is one of the most common complications of obesity, as well as a major risk factor for stroke, myocardial infarction, heart failure, and chronic kidney disease. 5 It is estimated that by 2025, approximately 1.5 billion people worldwide will be affected by hypertension. 6 A study including one million people in China from 2014 to 2017 showed that nearly half of adults aged 35–75 years suffer from hypertension, with approximately 22.5% of the people with hypertension being obese. 7 Obesity-induced hypertension has diverse, interrelated pathogenic mechanisms, which complicates treatment. Many patients with obesity struggle to control their weight and blood pressure through diet and lifestyle changes and require treatment with drugs, such as orlistat, liraglutide, or bariatric surgery. 8 First-line treatments for obesity-related hypertension currently include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II (ANG II) receptor blockers, and calcium channel blockers. 9 Sodium-glucose cotransporter 2 is mainly expressed in the proximal convoluted tubules of the kidney and is involved in glucose reabsorption. SGLT-2 inhibitors, a new class of drugs currently used to treat type 2 diabetes mellitus (T2DM), reduce blood glucose levels by increasing glucose excretion in the urine. This mechanism is insulin-independent, thus reducing the risk of hypoglycemia. More and more evidence suggests that SGLT-2 inhibitors have renal and cardiovascular protective effects in both diabetic and non-diabetic patients; thus, they are used in the treatment of heart failure and chronic kidney diseases. 10–13 In addition, SGLT-2 inhibitors have been found to reduce body weight and blood pressure. Weight loss is a critical component in the treatment of patients with obesity-related hypertension. Therefore, SGLT-2 inhibitors may be a new option over the current first-line drug treatment of obesity-related hypertension. This review discusses the beneficial effects of SGLT-2 inhibitors targeting the pathogenic mechanisms of obesity-associated hypertension (Figure 1). Figure 1 The mechanisms of SGLT-2 inhibitors for the treatment of obesity-associated hypertension. Taking sympathetic nervous system, renin-angiotensin-aldosterone system, insulin resistance, hyperleptinemia, renal insufficiency, inflammatory response and endothelial function as the main -Abstract Truncated-
endocrinology & metabolism